Shelter Pharma Other Announcement
Shelter Pharma cancelled its H2 FY2026 Investor Conference Call scheduled for June 10, 2026. A revised date will be announced later, delaying management's performance update.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements with these filters
Shelter Pharma cancelled its H2 FY2026 Investor Conference Call scheduled for June 10, 2026. A revised date will be announced later, delaying management's performance update.
Shelter Pharma completed a ₹1.35 Crore export order for Taha Drugs & Chemicals. Dispatch to Sudan has commenced, marking successful contract execution and revenue realization.
Shelter Pharma received a manufacturing license renewal for Ayurvedic products from the Government of Gujarat. The license is valid until September 2030, ensuring uninterrupted operations.
Shelter Pharma reported zero deviation in utilizing ₹25.31 Crore raised via preferential warrant issues. Funds were fully deployed toward working capital requirements as approved.
Shelter Pharma Ltd reported revenue from operations of ₹39.8 Cr (+49.6% YoY) and net profit of ₹4.5 Cr (+21.6% YoY) for H2 FY26.
Shelter Pharma reported a net profit of ₹9.03 Crore for the financial year ended March 31, 2026. The board also appointed CA Ismail Lakhani as internal auditor.
Shelter Pharma scheduled a Board Meeting for May 28, 2026, to approve audited financial results. The meeting covers performance for the half-year and full-year ended March 2026.
Shelter Pharma reports continuous positive customer feedback for its healthcare products across various platforms. This trend strengthens brand credibility and supports long-term growth prospects.
Shelter Pharma will participate in the iPHEX 2026 exhibition at Bharat Mandapam. This strategic move aims to enhance global visibility and explore new export opportunities.
Shelter Pharma successfully conducted a CME program in Patna attended by 32 doctors. The session strengthened product awareness and professional relationships within the medical fraternity.